KilgourMD, a brand focused on scalp health and hair growth, announced significant results from a Phase II clinical trial assessing its innovative hair loss system on February 19, 2026. Founded by board-certified dermatologist Dr. James Kilgour, the study evaluated the effectiveness of the KilgourMD System, which includes Prevention and Treatment Serums, among 43 menopausal women experiencing androgenetic alopecia—a group often overlooked in hair loss research.
The four-month trial aimed to ensure that the results were clinically meaningful by requiring participants to demonstrate a clinically significant level of hair loss. In contrast to many previous studies, which often relied on consumer perception, this research utilized objective measures evaluated by dermatologists. The findings revealed notable regrowth and a reduction in hair shedding, establishing a new benchmark for treatments in this demographic.
By day 120, 53% of participants achieved at least a half-grade improvement on the modified Female Ludwig scale, which dermatologists recognize as a significant visual change. Additionally, 26% of participants experienced a full grade improvement, an outcome comparable to those typically observed after six to twelve months of established pharmaceutical therapies such as minoxidil or finasteride.
The study highlighted an average improvement of 11.1% in the Ludwig score across the entire cohort within just four months. Furthermore, standardized assessments indicated a remarkable 60% reduction in hair shedding by the end of the trial, suggesting an accelerated normalization of the hair growth cycle and enhanced follicular health. Notably, improvements in hair shedding were recorded as early as day 45, with over 95% of participants showing a decrease in terminal hair shedding.
To ensure the validity of the results, two independent board-certified dermatologists graded the regrowth outcomes, supported by high-resolution imaging that confirmed visible enhancements in hair density and scalp coverage over time. Consumer feedback corroborated these clinical findings, with more than 80% of participants reporting noticeable improvements in hair density, health, and overall appearance by the conclusion of the study.
Dr. James Kilgour emphasized the significance of this research, stating, “Menopausal women have been largely excluded from rigorous hair loss research, despite experiencing some of the most challenging and persistent forms of thinning. This study validates not only the performance of the KilgourMD System but also the importance of designing and testing solutions specifically for this population.”
The promising results position KilgourMD as a leader in evidence-based solutions for hair loss, demonstrating that clinically meaningful regrowth and reduced shedding can occur in a matter of months rather than years. The complete findings from the trial are currently undergoing peer review and are anticipated to be published later this year.
Founded by Dr. Kilgour, KilgourMD aims to revolutionize hair care by prioritizing scalp health. The brand emerged from a personal journey, inspired by the struggles of Dr. Kilgour’s mother with menopause-related hair loss. KilgourMD employs advanced formulas and proprietary technologies designed to address scalp aging and improve hair thinning for individuals of all genders and hair types, with a focus on both prevention and treatment to promote long-term scalp health and fuller, stronger hair.
